MX2016012855A - Receptores de antigeno quimerico especifico de cd33 para inmunoterapia de cancer. - Google Patents

Receptores de antigeno quimerico especifico de cd33 para inmunoterapia de cancer.

Info

Publication number
MX2016012855A
MX2016012855A MX2016012855A MX2016012855A MX2016012855A MX 2016012855 A MX2016012855 A MX 2016012855A MX 2016012855 A MX2016012855 A MX 2016012855A MX 2016012855 A MX2016012855 A MX 2016012855A MX 2016012855 A MX2016012855 A MX 2016012855A
Authority
MX
Mexico
Prior art keywords
receivers
specific chemical
cancer immunotherapy
chemical antigen
antigen
Prior art date
Application number
MX2016012855A
Other languages
English (en)
Other versions
MX370788B (es
Inventor
Galetto Roman
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50486692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016012855(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellectis filed Critical Cellectis
Publication of MX2016012855A publication Critical patent/MX2016012855A/es
Publication of MX370788B publication Critical patent/MX370788B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con Receptores de Antígeno Quiméricos (CAR) que son proteínas quiméricas recombinantes capaces de redireccionar la especificidad y reactividad de la célula inmune hacia antígenos de membrana seleccionados, y más particularmente en los cuales la unión de ligando extracelular es un scFV derivado de un anticuerpo monoclonal CD33, confiriendo una inmunidad específica contra células CD33 positivas. Las células inmunes modificadas dotadas con dichos CARs son particularmente apropiadas para tratar linfomas y leucemias.
MX2016012855A 2014-04-03 2015-04-02 Receptores de antígeno quimérico específico de cd33 para inmunoterapia de cáncer. MX370788B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201470171 2014-04-03
PCT/EP2015/057331 WO2015150526A2 (en) 2014-04-03 2015-04-02 Cd33 specific chimeric antigen receptors for cancer immunotherapy

Publications (2)

Publication Number Publication Date
MX2016012855A true MX2016012855A (es) 2016-12-12
MX370788B MX370788B (es) 2020-01-06

Family

ID=50486692

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012855A MX370788B (es) 2014-04-03 2015-04-02 Receptores de antígeno quimérico específico de cd33 para inmunoterapia de cáncer.

Country Status (13)

Country Link
US (3) US9944702B2 (es)
EP (1) EP3126390B2 (es)
JP (1) JP6673848B2 (es)
KR (1) KR102170533B1 (es)
CN (1) CN106795221B (es)
AU (1) AU2015239069B2 (es)
CA (1) CA2944528C (es)
DK (1) DK3126390T3 (es)
ES (1) ES2765710T3 (es)
IL (1) IL247917B (es)
MX (1) MX370788B (es)
RU (1) RU2701341C2 (es)
WO (1) WO2015150526A2 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
AU2015239069B2 (en) * 2014-04-03 2020-02-20 Cellectis CD33 specific Chimeric Antigen Receptors for cancer immunotherapy
AU2015248956B2 (en) 2014-04-14 2020-06-25 Cellectis BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
MX2018004546A (es) * 2015-10-16 2019-04-15 Univ Columbia Composiciones y métodos para la inhibicion de antígenos específicos de linaje.
DK3368571T5 (da) * 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
JP7208010B2 (ja) * 2016-03-29 2023-01-18 ユニバーシティ オブ サザン カリフォルニア 癌を標的とするキメラ抗原受容体
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
JP7591342B2 (ja) * 2016-06-08 2024-11-28 プレシゲン，インコーポレイテッド Ｃｄ３３特異的キメラ抗原受容体
KR20190127655A (ko) 2016-10-19 2019-11-13 프로디자인 소닉스, 인크. 음향학에 의한 친화성 세포 추출
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
BR112019017751A2 (pt) 2017-02-28 2020-04-07 Vor Biopharma, Inc. composições e métodos de inibição de proteínas de linhagem específica
WO2018175988A1 (en) * 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
BR112019021182A2 (pt) 2017-04-24 2020-06-02 Memorial Sloan Kettering Cancer Center Agentes de anticorpo anti-cd33
WO2018213467A1 (en) 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
BR112020001207A2 (pt) 2017-07-20 2020-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. composições e métodos para atingir cânceres expressando cd33
WO2019067677A1 (en) 2017-09-29 2019-04-04 Cell Design Labs, Inc. METHODS OF MANUFACTURING RECEPTORS OF ANTI-CD307E ANTI-BACTERIAL CHIMERIC ANTIGENS AND USES THEREFOR
WO2019084234A1 (en) * 2017-10-26 2019-05-02 St. Jude Childen's Research Hospital, Inc. METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS
GB201719646D0 (en) * 2017-11-27 2018-01-10 Bivictrix Therapeutics Ltd Therapy
EP3720559A4 (en) * 2017-12-04 2021-10-06 Actinium Pharmaceuticals, Inc. METHODS OF TREATMENT OF PATIENTS WITH MYELODYSPLASIC SYNDROMES
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響トランスデューサドライバ及びコントローラ
CN108047333B (zh) * 2018-01-15 2021-05-25 浙江阿思科力生物科技有限公司 以cd33为靶点的特异性抗体、car-nk细胞及其制备和应用
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
US20210017277A1 (en) * 2018-03-14 2021-01-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Anti-cd33 chimeric antigen receptors and their uses
US12280119B2 (en) 2018-03-23 2025-04-22 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
AR115052A1 (es) * 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
CN110551741A (zh) * 2018-06-01 2019-12-10 上海恒润达生生物科技有限公司 靶向cd33的嵌合抗原受体及其用途
EP3802615A4 (en) * 2018-06-04 2022-04-13 Precigen, Inc. Muc16 specific chimeric antigen receptors and uses thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CA3102641A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
CN110856724B (zh) * 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
US11389485B2 (en) 2018-08-28 2022-07-19 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
EP3849565A4 (en) * 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
KR20210125978A (ko) 2018-11-01 2021-10-19 그라셀 바이오테크놀로지스 (상하이) 컴퍼니, 리미티드 T 세포 조작을 위한 조성물 및 방법
CN113227141A (zh) * 2018-11-07 2021-08-06 克里斯珀医疗股份公司 抗cd33免疫细胞癌症疗法
US12291560B2 (en) 2018-12-14 2025-05-06 Regeneron Pharmaceuticals, Inc. Dimerizing agent regulated immunoreceptor complexes
CA3126677A1 (en) * 2019-01-16 2020-07-23 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
WO2020219425A1 (en) * 2019-04-25 2020-10-29 Seattle Children's Hospital (dba Seattle Children's Research Institute) Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias
CA3133333A1 (en) 2019-04-30 2020-04-30 Brian Scott GARRISON Chimeric receptors and methods of use thereof
EP3966251A4 (en) * 2019-05-08 2023-05-10 Inhibrx, Inc. IMMUNOTHERAPIES TARGETED AGAINST CD33
JP7631234B2 (ja) * 2019-05-31 2025-02-18 シティ・オブ・ホープ Ｃｄ３３陽性悪性腫瘍治療用ｃｄ３３標的化キメラ抗原受容体修飾ｔ細胞
US12109235B2 (en) 2019-06-21 2024-10-08 Kite Pharma, Inc. TGF-beta receptors and methods of use
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
CA3172691A1 (en) * 2020-03-31 2021-10-07 Cameron J. Turtle Chimeric antigen receptors targeting cd33
EP4126925A4 (en) * 2020-03-31 2024-07-24 Fred Hutchinson Cancer Center CHIMERIC ANTIGEN RECEPTORS TARGETED AGAINST CD33
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
EP4263609A1 (en) 2020-12-17 2023-10-25 F. Hoffmann-La Roche AG Anti-hla-g antibodies and use thereof
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
AU2022291365B2 (en) 2021-06-08 2026-03-12 Kite Pharma, Inc. Gpc3 binding molecules
WO2022266075A1 (en) 2021-06-14 2022-12-22 Caribou Biosciences, Inc. Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
CN113527435B (zh) * 2021-07-14 2022-06-07 呈诺再生医学科技(珠海横琴新区)有限公司 对前列腺癌细胞特异性识别的新型多肽及其衍生物与应用
GB202204386D0 (en) * 2022-03-28 2022-05-11 Cambridge Entpr Ltd Engineered immune cell platform
WO2025008108A1 (en) 2023-07-06 2025-01-09 Miltenyi Biotec B.V. & Co. KG Immune cell expressing chimeric antigen receptor and transgenic t cell receptor
WO2026008700A1 (en) 2024-07-03 2026-01-08 Immunofusion Bv Il7r alpha signalling domain, chimeric antigen receptor and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
EP0659439B1 (en) * 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunoconjugates
DK1578446T3 (en) * 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
DE102009045006A1 (de) * 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
ES2717629T3 (es) * 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
AU2015239069B2 (en) * 2014-04-03 2020-02-20 Cellectis CD33 specific Chimeric Antigen Receptors for cancer immunotherapy
AU2015248956B2 (en) * 2014-04-14 2020-06-25 Cellectis BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy

Also Published As

Publication number Publication date
CA2944528C (en) 2021-08-10
ES2765710T3 (es) 2020-06-10
IL247917B (en) 2020-11-30
RU2701341C2 (ru) 2019-09-25
KR102170533B1 (ko) 2020-10-27
IL247917A0 (en) 2016-11-30
EP3126390B1 (en) 2019-10-16
JP2017515460A (ja) 2017-06-15
KR20170002412A (ko) 2017-01-06
WO2015150526A3 (en) 2015-11-26
US20190002561A1 (en) 2019-01-03
RU2016143155A3 (es) 2018-10-23
MX370788B (es) 2020-01-06
EP3126390A2 (en) 2017-02-08
EP3126390B2 (en) 2026-01-07
WO2015150526A2 (en) 2015-10-08
US9944702B2 (en) 2018-04-17
AU2015239069B2 (en) 2020-02-20
RU2016143155A (ru) 2018-05-04
US20240182565A1 (en) 2024-06-06
JP6673848B2 (ja) 2020-03-25
CN106795221A (zh) 2017-05-31
CA2944528A1 (en) 2015-10-08
BR112016022369A2 (pt) 2017-10-10
DK3126390T3 (da) 2020-01-20
CN106795221B (zh) 2022-06-07
AU2015239069A1 (en) 2016-10-06
US20170145094A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
MX2016012855A (es) Receptores de antigeno quimerico especifico de cd33 para inmunoterapia de cancer.
AR104718A1 (es) Receptores de antígenos quiméricos específicos de anti-gd3 para inmunoterapias contra el cáncer
BR112017001821A2 (pt) receptores de antígenos quiméricos específicos de ror1 (ntrkr1) para imunoterapia de câncer
MX2019012244A (es) Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
MX2017001229A (es) Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer.
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
CL2016002195A1 (es) Receptor antigénico quimérico car con dominios de unión a antígenos a la región constante del receptor de células t beta
MX389021B (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
PH12018500861A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
MX2019001184A (es) Anticuerpos anti-idiotípicos y métodos relacionados.
BR112017013981A2 (pt) receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
MX2018001739A (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos.
MX2017012939A (es) Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
MX2020007021A (es) Receptor quimerico de antigeno anti-cd19 humanizado.
NI201500103A (es) Anticuerpos cd47 que no agotan plaquetas ni glóbulos rojos y métodos de uso de los mismos.
MX2017001597A (es) Anticuerpos anti-pd-l1.
PE20161392A1 (es) Combinacion de lenalidomida y constructo de polipeptido, y sus usos
CU24494B1 (es) Anticuerpos y receptores de antígeno quiméricos específicos para cd19
AR096274A1 (es) Receptor quimérico de antígeno específico para cd19 y sus usos
MX2016011809A (es) Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos.
NZ733248A (en) Enzyme-linked immunosorbent assay (elisa) for the detection of anti-mycoplasma hyorhinis igg in swine serum
WO2014145940A3 (en) Hybridoma clones and monoclonal antibodies to cd9
AR111131A1 (es) Receptores de antígenos quiméricos para melanoma y usos de estos

Legal Events

Date Code Title Description
FG Grant or registration